Amgen Inc (AMGN): Shareholders' Equity
$8.66B
As of 2025-12-31
$11.69B
As of 2026-06-30
+33.2%
3-year compound annual growth
-1.6%
5-year compound annual growth
-11.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.66B | +47.3% | 2026-02-13, Balance as of period end |
| 2024-12-31 | $5.88B | -5.7% | 2026-02-13, Balance as of period end |
| 2023-12-31 | $6.23B | +70.2% | 2026-02-13, Balance as of period end |
| 2022-12-31 | $3.66B | -45.4% | 2025-02-14, Balance as of period end |
| 2021-12-31 | $6.70B | -28.8% | 2025-02-14, Balance as of period end |
| 2020-12-31 | $9.41B | -2.7% | 2024-02-14, Balance as of period end |
| 2019-12-31 | $9.67B | -22.6% | 2023-02-09, Balance as of period end |
| 2018-12-31 | $12.50B | -50.5% | 2022-02-16, Balance as of period end |
| 2017-12-31 | $25.24B | -15.5% | 2020-02-12, Balance as of period end |
| 2016-12-31 | $29.88B | +6.4% | 2019-02-13, Balance as of period end |
| 2015-12-31 | $28.08B | +8.9% | 2018-02-13, Balance as of period end |
| 2014-12-31 | $25.78B | +16.7% | 2017-02-14, Balance as of period end |
| 2013-12-31 | $22.10B | +15.9% | 2016-02-16, Balance as of period end |
| 2012-12-31 | $19.06B | +0.2% | 2015-02-19, Balance as of period end |
| 2011-12-31 | $19.03B | -20.5% | 2014-02-24, Balance as of period end |
| 2010-12-31 | $23.94B | +5.6% | 2013-02-27, Balance as of period end |
| 2009-12-31 | $22.67B | +8.5% | 2012-02-29, Balance as of period end |
| 2008-12-31 | $20.89B | +12.8% | 2011-02-25, Balance as of period end |
| 2007-12-31 | $18.51B | n/a | 2010-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Amgen Inc (AMGN) | 2025-12-31 | $8.66B | +47.3% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $22.62B | +17.5% |
| Biogen Inc. (BIIB) | 2025-12-31 | $18.26B | +9.2% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $3.78B | +5.9% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
Compare AMGN, GILD, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗